Use of canakinumab in the cryopyrin-associated periodic syndrome.

By H. Lachmann, I. Koné-Paut, J. Kuemmerle-Deschner, K. Leslie, E. Hachulla, P. Quartier, X. Gitton, A. Widmer, N. Patel, P. Hawkins. New England Journal of Medicine, 2009

735 citations recorded by the source corpus.

Subfields: Molecular Biology, Pulmonary and Respiratory Medicine, Rheumatology

View Paper: https://www.semanticscholar.org/paper/8f604ae8457b9afd2dde817949831abebe02cad2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. M. Lamkanfi
2. V. Dixit
3. Kate Schroder
4. P. Ridker
5. C. A. Dinarello
6. Peter Libby
7. T. Mak
8. T. Berger

In Pulmonary and Respiratory Medicine

1. C. A. Dinarello
2. P. Ridker

In Rheumatology

1. Peter Libby
2. C. A. Dinarello
3. P. Ridker

Citations in the corpus

• Anti-inflammatory Agents: Present and Future (2010, positive): “Canakinumab is approved for the treatment of a group of autoinflammatory diseases now termed cryopyrin-associated periodic syndromes (CAPS) that includes familial cold autoinflammatory syndrome, Mucle-Wells syndrome, and Neonatal Onset Multiinflammatory Disease (see Essay by D.L. Kastner et al. in t”
• Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). (2011, background): “Multiple clinical observations support the concept that a net balance of inflammatory activity influenced by relative levels of IL-1 and IL-1Ra contributes to human disease.26-29 First, specific amino acid mutations altering the NLRP3 inflammasome can increase secretion of IL-1β and result in a grou”
• Caspase functions in cell death and disease. (2013, background): “Newer agents include monoclonal antibodies (mAbs) directed against IL-1b (canakinumab) (Alten et al. 2008; Church and McDermott 2009; Lachmann et al. 2009a), and IL-1Trap, a decoy receptor with high affinity for IL-1 (Kalliolias and Liossis 2008).”
• The inflammasomes. (2010, positive): “Mechanisms by which inflammasome activation and elevated IL-1 b may drive the progression from obesity to T2D are reviewed elsewhere in detail (Schroder et al., 2010).”
• Inflammasomes and their roles in health and disease. (2012, background): “This is also illustrated by the successful application of IL-1 inhibitors in patients suffering from hereditary autoinflammatory disorders, gouty arthritis, and type II diabetes (Lachmann et al. 2009, Lamkanfi et al. 2011, Larsen et al. 2007).”
• Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. (2012, neutral): “Abdominal pain 3 (7) 1 (2) 26 (15) 8 (16) 6 (12)”